Role of High-Density Lipoprotein Cholesterol (HDL-C) as a Clinical Predictor of Decompensation in Patients with Chronic Liver Disease (CLD)

Table 1

Distribution of variables among patients with decompensation events on follow-up as compared to patients with decompensation.

Baseline characteristics of the population	Total
Mean age (, years)
Gender distribution ( (%))
Male	147 (86.5)
Female	23 (13.5)
Median duration of CLD at recruitment (days)	1121
Etiology of CLD ( (%))
Alcohol	74 (43.5)
Viral hepatitis	11 (6.4)
Cryptogenic	85 (50)
Comorbidities ( (%))
Diabetes mellitus	110 (64.7)
Systemic hypertension	51 (30)
Coronary artery disease	19 (11.2)
Chronic kidney disease	30 (17.6)
Child status ( (%))
Child A	37 (21.8)
Child B	32 (18.8)
Child C	101 (59.4)
Mean MELD score ()
Past history of complications of CLD ( (%))
Varices on endoscopy	126 (74.11)
Ascites	95 (55.88)
Hepatic encephalopathy	44 (25.88)
Variceal bleed	41 (24.11)
Laboratory parameters: ()
Total cholesterol
High-density lipoprotein
Low-density lipoprotein
Total leucocyte count
Platelet count
Creatinine
Sodium
Potassium
Albumin
INR
C-reactive protein
Neutrophil-lymphocyte ratio (NLR)
Total decompensation events at follow-up ( (%))	97 (57.05)
Ascites	67 (69.07)
Hepatic encephalopathy	41 (42.26)
Hepatorenal syndrome	45 (46.39)
Variceal bleed	20 (20.61)
Mortality ( (%))	43 (25.3)

Abbreviations: CLD: chronic liver disease; MELD score: model for end-stage liver disease; INR: international normalized ratio.